A new frontier for medical device trust and patient safety

Tern plc

As clinical environments become increasingly digital and interconnected, medical devices no longer operate in isolation. They link into hospital networks, share data across platforms, interface with cloud services and increasingly fall under regulatory scrutiny. That means the device manufacturers and healthcare providers face new challenges, including how to establish trust, how to manage devices through their lifecycle, and how to ensure compliance with evolving standards. Device Authority’s KeyScaler platform presents itself as a technology to address exactly these challenges in the realm of the Internet of Medical Things (IoMT).

At a fundamental level the platform begins with device trust. Each device must be registered, authenticated and clearly identified before it transmits patient data or interfaces with clinical systems. Once that trust anchor is in place, KeyScaler automates credential issuance and lifecycle management so that as devices are deployed, maintained, updated or retired the identity and certificate infrastructure is managed at scale.

Connected devices are generating streams of sensitive patient information, system telemetry and operational metrics. Encryption, secure updates and policy‑driven access become mandatory. The KeyScaler platform emphasises end‑to‑end encryption, including the ability to manage data both at rest and in transit, and to enforce policies on how and when keys can be used.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Search